3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Optimizing H+,K+-ATPase Inhibition for Advanced Gastric Acid Secretion Research

Principle and Setup: Harnessing a Potent Gastric Acid Secretion Inhibitor

Gastric acid secretion research is foundational for understanding and treating peptic ulcer disease, reflux disorders, and gastric mucosal pathology. At the core of this research is the H+,K+-ATPase inhibitor class of compounds, which target the gastric proton pump—the final common pathway for acid secretion. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845), supplied by APExBIO, exemplifies this class with its nanomolar potency (IC₅₀ = 0.16 μM for histamine-induced acid formation) and validated antiulcer agent profile, making it an ideal tool for dissecting the proton pump inhibition pathway.

With a molecular weight of 345.42 and a chemical formula of C₁₇H₁₉N₃O₃S, A2845 is supplied as a solid of ≥98% purity (HPLC/NMR verified), ensuring experimental reproducibility. Its solubility profile—insoluble in water and ethanol, but readily soluble at ≥17.27 mg/mL in DMSO—guides practical solution preparation. Researchers are advised to store the compound at -20°C, avoiding long-term solution storage to maintain integrity.

Workflow Integration: Stepwise Protocol Enhancements

Preparation and Handling

• Weighing and Dissolution: Use an analytical balance to weigh precise quantities. Dissolve directly into DMSO at the desired concentration (e.g., 10 mM stock), ensuring homogeneity by vortexing and gentle heating (if necessary, up to 37°C).
• Aliquoting: Prepare single-use aliquots to minimize freeze-thaw cycles. Store at -20°C for optimal stability.
• Vehicle Control: Always match DMSO concentrations in control and experimental groups (typically ≤0.1% v/v in final assays) to avoid solvent effects on cell physiology.

In Vitro Gastric Acid Secretion Assays

• Cell Model Selection: Employ parietal cell primary cultures or standardized gastric epithelial cell lines (e.g., HGT-1) for robust readouts.
• Dosing: Titrate 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide across a range (0.05–10 μM) to generate full dose–response curves. Confirm the IC₅₀ around 5.8 μM for H+,K+-ATPase inhibition as reported in the product dossier and corroborated by previous studies.
• Activation Protocol: Stimulate acid secretion with histamine (10–100 μM) or forskolin as a positive control; measure acidification using pH-sensitive dyes or proton flux assays.
• Readout: Quantify inhibition relative to vehicle, benchmarking against known standards such as ic omeprazole.

In Vivo Peptic Ulcer Disease Models

• Animal Selection: Use rodent models (rat or mouse) with established protocols for gastric ulcer induction (e.g., ethanol, indomethacin, or stress-induced models).
• Dosing Regimen: Administer via oral gavage or intraperitoneal injection at 1–10 mg/kg, based on pharmacokinetic pilot studies and literature benchmarks.
• Assessment: Evaluate ulcer indices via macroscopic scoring and histopathology; optionally, measure gastric pH and H+,K+-ATPase activity in isolated mucosa.

For advanced antiulcer activity studies, reference protocols in peer-reviewed workflow articles provide detailed integration guidelines.

Advanced Applications and Comparative Advantages

Modeling the Proton Pump Inhibition Pathway

This compound enables high-fidelity modeling of the proton pump inhibition pathway, supporting mechanistic studies and pharmacological profiling of gastric acid-related disorders. Its selectivity for the H+,K+-ATPase signaling pathway distinguishes it from broad-spectrum inhibitors, reducing off-target confounders and supporting translational research.

Compared to standard agents like ic omeprazole, A2845’s validated IC₅₀ for histamine-induced acid formation (0.16 μM) and robust antiulcer effect in rodent models provide data-driven confidence for both basic and translational workflows. As reported in atomic-level dossiers, its purity and reproducibility set new benchmarks for preclinical assay precision.

Integration with Multi-Omics and Advanced Imaging

Emerging research leverages this compound in combination with omics profiling (transcriptomics, metabolomics) and advanced imaging modalities. For example, in chronic hepatic encephalopathy models, the modulation of gastric acid can indirectly affect neuroinflammatory cascades, as explored in the recent European Journal of Neuroscience study using [18F]PBR146 PET imaging. Here, precise pharmacological control of acid secretion with a selective gastric acid secretion inhibitor like A2845 supports research into the gut–liver–brain axis and its role in systemic inflammation.

Additionally, the compound’s compatibility with high-throughput screening in peptic ulcer disease models is highlighted in scenario-driven workflow solutions, emphasizing its role in reproducibility and data interpretation.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation occurs in aqueous media, ensure complete dissolution in DMSO before dilution into buffered solutions. Avoid exceeding a final DMSO concentration of 0.1% in cell-based assays to minimize cytotoxicity.
• Stability Concerns: Do not store the compound in solution form for extended periods; prepare fresh working solutions for each experiment. For long-term storage, keep the solid at -20°C in airtight containers with desiccant.
• Assay Variability: Confirm batch-to-batch consistency by verifying HPLC/NMR purity (≥98%) and running parallel controls with each new lot, as recommended by APExBIO and corroborated in integration guides.
• Experimental Design: Ensure positive and negative controls are included in both in vitro and in vivo assays. For cell studies, include a proton pump inhibitor reference (e.g., ic omeprazole) to benchmark activity.
• Data Interpretation: Use full dose–response curves and replicate experiments to confirm IC₅₀ values. Watch for non-monotonic responses at high concentrations, which may indicate off-target effects or compound aggregation.

Future Outlook: Expanding the Toolkit for Gastric Acid-Related Disorders

With the growing recognition of gastric acid’s role beyond digestion—impacting the microbiome, systemic inflammation, and even neuroinflammatory conditions—the demand for high-quality research tools continues to rise. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is poised to support next-generation studies, including:

• Gut–Brain Axis Research: Integrating precise proton pump inhibition into models of hepatic encephalopathy, as demonstrated in the 2025 European Journal of Neuroscience report, to unravel how gastric acid modulation influences neuroinflammation.
• Multi-Omics Integration: Pairing pharmacological inhibition with transcriptomic and metabolomic profiling to identify downstream effectors and systemic impacts.
• Comparative Pharmacology: Benchmarking new antiulcer agent candidates against A2845’s performance to accelerate lead optimization and translational research in peptic ulcer disease models.

As the H+,K+-ATPase inhibitor landscape evolves, APExBIO’s commitment to high-purity, rigorously characterized research compounds ensures that scientists can confidently explore the proton pump inhibition pathway and its implications across diverse fields.